Progresses and challenges in diagnosis and treatment of peripheral T/NK cell lymphomas
10.3969/j.issn.1000-8179.20141433
- VernacularTitle:外周T细胞及NK细胞淋巴瘤诊疗现状
- Author:
Yuqin SONG
- Publication Type:Journal Article
- Keywords:
peripheral T/NK cell lymphomas;
epidemiology;
therapy;
prognosis;
targeted drugs;
stem cell transplantation
- From:
Chinese Journal of Clinical Oncology
2014;(19):1208-1212
- CountryChina
- Language:Chinese
-
Abstract:
The peripheral T/NK cell lymphomas (PT/NKCLs) encompass a heterogeneous group of malignant lymphoid diseas-es, which derived from mature T-cells and NK cells. PT/NKCLs are rare, and its epidemiology and pathological subtypes showed signif-icant geographic and ethnic differences. PT/NKCLs, especially NK/T cell lymphoma (nasal type), are relatively common in Asian coun-tries. The use of an anthracycline-containing regimen is not associated with an improved outcome in most subtypes of PT/NKCLs, but is associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive. High-dosage chemotherapy combined with stem cell transplantation is a considerable choice for newly diagnosed high-risk or refractory/relapsed PT/NKCLs because of its general-ly poor clinical outcome. Advances in new drugs have lagged behind DLBCL because of the disease rarity of PT/NKCL and biological heterogeneity. Nevertheless, new chemotherapeutic drugs, such as pralatrexate and bendamustine, and targeted drugs, such as alemtu-zumab, brentuximab vedotin, HDAC inhibitors, bortezomib, and lenalidomide, are recently emerging effective therapies in this area. We confidently believe that the era of PT/NKCLs is coming.
